Germline CARD11 Mutation in a Patient with Severe Congenital B Cell Lymphocytosis

Andrew S Brohl1, Jeffrey R Stinson2, Helen C Su3

  • 1Oncogenomics Section, Genetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 37 Convent Drive, Building 37, Room 2016B, Bethesda, MD, 20892, USA.

Insights

A de novo CARD11 mutation caused severe congenital B cell lymphocytosis, a condition now termed BENTA disease. This genetic mutation leads to increased B cell proliferation and survival, impacting immune function.

Area of Science:

  • Immunology
  • Genetics
  • Molecular Biology

Background:

  • Germline CARD11 mutations are linked to congenital B cell lymphocytosis.
  • Understanding the genetic basis of immune dysregulation is crucial for developing targeted therapies.

Observation:

  • A patient presented with a decade-long history of severe polyclonal B lymphocytosis.
  • Whole exome sequencing identified a de novo germline G123D CARD11 mutation.
  • The mutation induced constitutive NF-κB activation and enhanced B cell receptor signaling.

Findings:

  • The patient's B cells showed increased expression of cell cycle genes, enhanced proliferation, and improved survival.
  • This de novo mutation resulted in more severe lymphocytosis than previously reported CARD11 mutations.
  • The findings suggest that CARD11 mutations can lead to B cell Expansion with NF-κB and T cell Anergy (BENTA) disease.

Implications:

  • This study identifies a novel de novo CARD11 mutation causing BENTA disease.
  • Further research is needed to understand the variable expressivity and regulatory factors of mutant CARD11.
  • Identifying specific genetic drivers of lymphocytosis can inform future therapeutic strategies.
Abstract